Tone mix
Week by week 52 weeks
Share of PTC Therapeutics, Inc.'s 190 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jan 19, 2026 · tone +100Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves+102
- Week of Jan 26, 2026 · tone +100Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves+100
- Week of Feb 9, 2026 · tone -99PTC Therapeutics Pulls FDA Application for Muscular Dystrophy Treatment-96
- Week of May 4, 2026 · tone +100PTC Therapeutics (PTCT) Reports Positive Huntington's Disease Trial Results+86
- Week of Aug 18, 2025 · tone -64PTC Therapeutics Stock Is Stuck In A Multi-Year Slump - PTC Therapeutics (NASDAQ:PTCT)-76
- Week of Jul 6, 2026 · tone +99PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High on Analyst Upgrade+75
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about PTC Therapeutics, Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 5 | +75 |
| Last 30 sessions | 12 | +31 |
| Last 90 sessions | 49 | +28 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, November 4, 2026
1 headline, average tone +86: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletStock Buyback Program Approved by PTC Therapeutics (NASDAQ:PTCT) BoardPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Stock Buyback Program Approved by PTC Therapeutics (NASDAQ:PTCT) Board | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
1 headline, average tone +97: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletPTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase ProgramPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program | www.prnewswire.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
2 headlines, average tone +98: 2 positive, 0 neutral and 0 negative. Showing all 2.
- econotimes.com · 1 outletPTC Therapeutics Raises 2026 Product Revenue Forecast After Sephience GrowthPositive
- seekingalpha.com · 1 outletPTC sees $960M-$990M 2026 product revenue as Sephience expands and ST-920 filing targets Q4 2026 (NASDAQ:PTCT)Positive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| PTC Therapeutics Raises 2026 Product Revenue Forecast After Sephience Growth | econotimes.com | 1 | Positive |
| PTC sees $960M-$990M 2026 product revenue as Sephience expands and ST-920 filing targets Q4 2026 (NASDAQ:PTCT) | seekingalpha.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outlet13,717 PTC Therapeutics, Inc. $PTCT Shares Sold by State of Alaska Department of RevenueNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| 13,717 PTC Therapeutics, Inc. $PTCT Shares Sold by State of Alaska Department of Revenue | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about PTC Therapeutics, Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.